

Paul Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12135473/publications.pdf>

Version: 2024-02-01

29
papers

2,108
citations

304743

22
h-index

477307

29
g-index

29
all docs

29
docs citations

29
times ranked

1282
citing authors

#	ARTICLE	IF	CITATIONS
1	The Drugs Don't Work. <i>Social Studies of Science</i> , 2003, 33, 327-364.	2.5	290
2	The pharmaceuticalisation of society? A framework for analysis. <i>Sociology of Health and Illness</i> , 2011, 33, 710-725.	2.1	268
3	The myth of the biotech revolution. <i>Trends in Biotechnology</i> , 2004, 22, 564-569.	9.3	200
4	Mapping the new molecular landscape: social dimensions of epigenetics. <i>New Genetics and Society</i> , 2013, 32, 429-447.	1.2	115
5	Capitalizing hope: the commercial development of umbilical cord blood stem cell banking. <i>New Genetics and Society</i> , 2008, 27, 127-143.	1.2	114
6	The role of social scientists in synthetic biology. <i>EMBO Reports</i> , 2009, 10, 201-204.	4.5	112
7	From Bedside to Bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells. <i>Science As Culture</i> , 2008, 17, 29-41.	3.2	104
8	Constituting neurologic subjects: Neuroscience, subjectivity and the mundane significance of the brain. <i>Subjectivity</i> , 2011, 4, 346-365.	0.4	91
9	The Standardization of Race and Ethnicity in Biomedical Science Editorials and UK Biobanks. <i>Social Studies of Science</i> , 2008, 38, 407-423.	2.5	89
10	Tailored Medicine: Whom Will it Fit? The Ethics of Patient and Disease Stratification. <i>Bioethics</i> , 2004, 18, 322-343.	1.4	84
11	Integrating pharmacogenetics into society: in search of a model. <i>Nature Reviews Genetics</i> , 2004, 5, 663-669.	16.3	80
12	Five rules of thumb for post-ELSI interdisciplinary collaborations. <i>Journal of Responsible Innovation</i> , 2016, 3, 73-80.	4.9	69
13	The Promissory Pasts of Blood Stem Cells. <i>BioSocieties</i> , 2006, 1, 329-348.	1.3	67
14	Racial Categories in Medicine: A Failure of Evidence-Based Practice?. <i>PLoS Medicine</i> , 2007, 4, e287.	8.4	63
15	Biobanks, national identity and imagined communities: The case of UK biobank. <i>Science As Culture</i> , 2006, 15, 237-251.	3.2	59
16	The changing brain: Neuroscience and the enduring import of everyday experience. <i>Public Understanding of Science</i> , 2015, 24, 878-892.	2.8	46
17	Commercialising neurofutures: Promissory economies, value creation and the making of a new industry. <i>BioSocieties</i> , 2015, 10, 422-443.	1.3	37
18	Have we seen the geneticisation of society? Expectations and evidence. <i>Sociology of Health and Illness</i> , 2017, 39, 989-1004.	2.1	32

#	ARTICLE	IF	CITATIONS
19	Genetic governance: The risks, oversight and regulation of genetic databases in the UK. <i>New Genetics and Society</i> , 2001, 20, 157-183.	1.2	31
20	Pharmaceuticals and society: Power, promises and prospects. <i>Social Science and Medicine</i> , 2015, 131, 193-198.	3.8	31
21	The use of large biological sample collections in genetics research: Issues for public policy. <i>New Genetics and Society</i> , 2000, 19, 165-191.	1.2	27
22	Genetic governance: the risks, oversight and regulation of genetic databases in the UK. <i>New Genetics and Society</i> , 2001, 20, 157-183.	1.2	26
23	The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. <i>Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences</i> , 2006, 37, 583-601.	1.3	21
24	Medicalization and pharmaceuticalization at the intersections: A commentary on Bell and Figert (2012). <i>Social Science and Medicine</i> , 2012, 75, 2129-2130.	3.8	15
25	Neuroscience and Medicalisation: Sociological Reflections on Memory, Medicine and the Brain. <i>Advances in Medical Sociology</i> , 2011, , 231-254.	0.1	11
26	Regenerative medicine in India: trends and challenges in innovation and regulation. <i>Regenerative Medicine</i> , 2017, 12, 875-885.	1.7	8
27	Risks and benefits may turn out to be finely balanced. <i>Nature</i> , 2009, 457, 532-532.	27.8	7
28	Evolving sociological analyses of "Pharmaceuticalisation": a reply to Abraham. <i>Sociology of Health and Illness</i> , 2011, 33, 729-730.	2.1	7
29	The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine. <i>Regulation and Governance</i> , 2021, 15, 969-986.	2.9	4